Fig. 1

Anti-CGRP MAbs ≥50% RR (A; C) and mean change in primary outcomes after 6 months of treatment (B; D) in study patients. In section A, we report ≥50% RR in HDM and MDM in CM patients with MO (light gray, 99/139) and without MO (dark gray, 40/139) at baseline. In section C, we also report ≥50% RR in patients with basal MO (99/139), comparing them according to their MO response after 6 months of treatment: MO resolution (light blue, 60/99) vs. MO ongoing (dark blue, 39/99). In section B, we report the mean change in HDM, MDM and AMDM after 6 months of treatment in CM patients with MO (light gray, 99/139) and without MO (dark gray, 40/139) at baseline. In section D, we also report the mean change in HDM, MDM and AMDM in patients with basal MO (99/139), comparing them according to their MO response after 6 months of treatment: MO resolution (light blue, 60/99) vs. MO ongoing (dark blue, 39/99). In green is shown the mean difference between Month 0 and Month 6 (Δ). ^** P-value < 0.01 (AB: Significance assessed with Fisher’s exact test; CD: Significance assessed with paired t-test). RR: Response Rate; MO: medication overuse; d/mo: days per month; p/mo: pills per month; HDM: headache days/month; MDM: migraine days/month; AMDM: acute medications days/month